Academic teams reported manufacturing and molecular strategies that significantly extend CAR‑T cell persistence in preclinical models. Albert Einstein College of Medicine investigators described a modular protein scaffold (HCW9206) linking IL‑7, IL‑15 and IL‑21 to produce CAR‑T products enriched for long‑lived T memory stem cells. The engineered cells showed prolonged control of hematologic malignancies and HIV models in mice compared with conventional protocols. Complementary manufacturing advances from another group introduced modular protein scaffolds and activation regimens to produce CAR‑T cells with enhanced durability and self‑renewal. Together these studies—published in Science Advances and related outlets—offer actionable tactics for sponsors to translate into next‑generation CAR‑T programs aimed at reducing relapse rates and broadening indications.